USPTO Patent Grant: Pharmaceutical Composition for Skin Disease

ChangeBridge: Patent Grants - Biotech (C12N)

Published March 24th, 2026

Detected March 24th, 2026

Summary

The USPTO has granted a patent (US12582680B2) to RIKEN for a pharmaceutical composition derived from ampicillin-sensitive bacteria to treat skin diseases. The patent covers bacterial cells, culture supernatants, extracts, and metabolites as active components.

View original document View source feed page

What changed

The United States Patent and Trademark Office (USPTO) has granted patent US12582680B2 to RIKEN for a pharmaceutical composition aimed at preventing, ameliorating, or treating skin diseases. The invention utilizes components derived from ampicillin-sensitive bacteria, including bacterial cells, culture supernatants, extracts, or metabolites, identified through research on Tmem79-knockout model mice.

This patent grant is primarily an intellectual property protection for RIKEN's research and development. For pharmaceutical companies and drug manufacturers, this represents a new piece of intellectual property in the dermatology and biotechnology space. While not imposing direct regulatory obligations, it may influence future research, development, and commercialization strategies in the treatment of skin diseases, potentially requiring licensing or collaboration for related product development.

Source document (simplified)

← USPTO Patent Grants

Pharmaceutical composition for prevention, amelioration, or treatment of skin disease

Grant US12582680B2 Kind: B2 Mar 24, 2026

Assignee

RIKEN

Inventors

Yoshihiro Ito, Kenya Honda, Masayuki Amagai, Eiryo Kawakami

Abstract

In the present invention, the influence by flora of the skin on dermatitis is examined by analyzing Tmem79-knockout model mice, and a bacterium having a suppressive effect on dermatitis is identified, and the present invention relates to a pharmaceutical composition derived from such a bacterium, containing as active components one or more substances selected from: (a) a bacterial cell of an ampicillin-sensitive bacterium, or a constituent component of the bacterium; (b) a culture supernatant of an ampicillin-sensitive bacterium, or a purified product from the culture supernatant; (c) an extract of an ampicillin-sensitive bacterium; and (d) a metabolite of an ampicillin-sensitive bacterium.

CPC Classifications

A23L 33/135 A23L 33/17 A23L 33/185 A61K 35/747 A61K 35/74 A61P 1/00 A61P 17/00 A61P 17/04 A61P 17/06 C12N 1/205 C12N 1/20 A01K 2217/075 C12R 2001/44 G01N 2800/202 C12Q 1/14